NRSN Neurosense Therapeutics Ltd
Company Analysis
Latest News
🔴 Neurosense Therapeutics is trading 9.7% down today as multi-day decline continues without fresh catalysts
Neurosense Therapeutics is trading at $0.43 (down 9.7%) as its multi-day decline continues despite no new company-specific news or catalysts. • The stock has...
🔴 Neurosense Therapeutics is trading 8.9% down today as multi-day slide continues
Neurosense Therapeutics is trading at $0.42 (-8.90%) in pre-market, extending a recent downward trend despite a lack of fresh company-specific catalysts. •...
NRSN Loses Its Footing After Brief Bounce: Can a Sub-Dollar Biotech Find a Floor?
Shares of Neurosense Therapeutics slid 7.4% to $0.44 on August 1, erasing a short-lived bargain-hunting bounce and extending a punishing selloff that has...
🔴 Neurosense Therapeutics is trading 7.6% down today following a $150 million shelf filing and going-concern warning
Neurosense Therapeutics is trading at $0.43 (-7.57%) in after-hours trading, extending a weak stretch following its $0.47 regular-session close on July 31,...
🔴 Neurosense Therapeutics is trading 7.4% down today as potential dilution from $150M securities shelf and going concern warning weigh on shares
• The decline follows NeuroSense Therapeutics' July 30, 2026, filing of a $150 million securities shelf offering, which permits the company to offer various...
🟢 Neurosense Therapeutics is trading 5% up today on bargain-hunting after recent selloff
Neurosense Therapeutics is trading at $0.50 (5% up) as investors engage in bargain-hunting following a series of sharp declines over the past week. • The...
🟢 Neurosense Therapeutics is trading 5% up today on bargain-hunting after recent selloff
Neurosense Therapeutics is trading at $0.50 (5% up) in after-hours trading as bargain hunters step in following a period of sharp declines. • The move extends...
🟢 Neurosense Therapeutics is trading 7.3% up today on bargain-hunting after recent selloff
Neurosense Therapeutics is trading 7.3% up at $0.52 as bargain hunters move in following a period of sharp declines. • The stock hit a low of $0.48 on July...
🟢 Neurosense Therapeutics is trading 5.6% up today on bargain-hunting after a sharp selloff
Neurosense Therapeutics is trading at $0.51 (+5.6%) in pre-market, extending an after-hours rebound from a sharp multi-day selloff that saw shares close at...
🟢 Neurosense Therapeutics is trading 8.3% up today as it rebounds from a sharp multi-day selloff
Neurosense Therapeutics is trading at $0.52 (up 8.3%) in after-hours trading, rebounding from a sharp decline to a $0.48 close on July 29, 2026. * The stock...
🔴 Neurosense Therapeutics is trading 11.36% down today amid broader biotech weakness and Nasdaq compliance concerns
Neurosense Therapeutics is trading 11.36% down today at $0.49, extending a multi-day slide despite a lack of fresh company-specific catalysts. • The downward...
🔴 Neurosense Therapeutics is trading 11.3% down today with no fresh news catalyst
Neurosense Therapeutics is trading 11.3% down today at $0.52 as the stock extends its decline without a fresh news catalyst. * The move comes with no new...
🔴 Neurosense Therapeutics is trading 13% down today, extending a week-long slide on no fresh news
Neurosense Therapeutics is trading 13% down at $0.51 in pre-market, extending a steady slide from $0.70 on July 21. • The stock has seen a consistent decline...
🔴 Neurosense Therapeutics is trading 8% down today amid intraday volatility
Neurosense Therapeutics is trading at $0.60 (-7.68%) today amid intraday volatility, as no new company-specific catalysts have been identified to explain the...
NeuroSense Eyes Canadian Approval for Its ALS Drug — But Can a $25 Million Company Actually Bring It to Market?
Shares of NeuroSense Therapeutics shifted sharply higher on July 24, climbing 10.5% to $0.72, after the company announced it will file for Canadian approval of...
🟢 Neurosense Therapeutics is trading 10.5% up today on plans to file Health Canada submission for ALS drug PrimeC
Neurosense Therapeutics is trading at $0.72 (10.5% up) following its announcement to file a New Drug Submission with Health Canada for its ALS therapy,...
NeuroSense to seek Canadian PrimeC approval, citing long-term survival benefit
NeuroSense Therapeutics announced plans on July 22, 2026, to file a New Drug Submission (NDS) with Health Canada for PrimeC. The company expects to complete...
🔴 Neurosense Therapeutics is trading 13.5% down
Neurosense Therapeutics is trading at $0.59, down 13.5% from a comparison close of $0.68 during regular trading. This is a price-action follow-up, so a...
NeuroSense Advances ALS Drug PrimeC, Reducing Protein Linked to 97% of Cases
NeuroSense Therapeutics (NASDAQ: NRSN) met the primary efficacy endpoint in its Phase 2b PARADIGM trial. The study evaluated the ALS drug candidate PrimeC....
🔴 NRSN is trading 5.5% down today after meeting Phase 2b ALS study endpoint
NRSN is trading 5.5% down now at $0.72 after announcing it achieved the primary endpoint in its Phase 2b ALS study, a key milestone for its lead asset...